The Company published its Periodic Report for the 1 half of 2017.
- The total value of sales generated by the Company in the first half of 2017 amounted to 57 million net, whereas net profit to over 13 million.
- In terms of volume, the sales of specialised medicinal products which are Polish market leaders in their respective therapeutic categories reached the growth rate of 10%.
- The export value is in line with the Company’s expectations and shows prospect for growth in subsequent months of 2017;
- Promising results of R&D projects in the field of innovative therapies will enable i.a. a formal launching of the clinical development for 3 drug candidates by the end of 2017.
We also invite you to read the report and material with a commentary of the Company’s Management Board.